TEWKSBURY, Mass.--(BUSINESS WIRE)--Mitralign will present updates on its mitral and tricuspid valve repair platform at the Transcatheter Cardiovascular Therapeutics (TCT) conference Oct 11-15 in San Francisco. As a part of conference updates, the company will also provide details on the SCOUT study utilizing its TriAlignTM Tricuspid Percutaneous Valve Annuloplasty System as part of an Early Feasibility Investigational Device Exemption (IDE) approved by the FDA. The SCOUT study will be a multi-center U.S. study and will commence patient enrollment in Q4 2015.
Help employers find you! Check out all the jobs and post your resume.
